肝疾患治療：世界市場

世界の肝疾患治療の市場規模は、2024年の460億米ドルから、予測期間中は7.1%のCAGRで推移し、2030年には691億米ドルに達すると予測されています。

北米市場は、2024年の208億米ドルから、予測期間中はCAGR 7.3%で推移し、2030年には316億米ドルに達すると予測されています。アジア太平洋市場は、2024年の69億米ドルから、予測期間中はCAGR 7.9%で推移し、2030年には108億米ドルに達すると予測されています。

当レポートでは、世界の肝疾患治療の市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、パイプライン分析、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

• 市場見通し
• 調査範囲
• 市場サマリー

第2章 市場概要

• 概要
• 疾患および製品別の治療の分類
• 肝炎
• 肝腫瘍・肝癌
• 自己免疫性肝疾患
• アルコール性肝疾患
• 慢性肝疾患
• 非アルコール性脂肪性肝疾患
• マクロ経済要因の分析
• 人口動態と高齢化
• 世界経済の成長
• 地政学的リスク、貿易戦争、サプライチェーンの混乱
• 国民の意識向上と教育
• ポーターのファイブフォース分析

第3章 市場力学

• 概要
• 市場促進要因
• 肝疾患の発生率の増加
• アルコールの摂取と不適切な食事
• ワクチンの提供と意識向上に向けた政府の取り組み
• 市場抑制要因
• FDAの承認と厳格な政府規制
• 薬に伴う副作用とリスク
• 市場機会
• 治療選択肢の進歩
• 新興市場と治療へのアクセス

第4章 規制状況

• 世界の規制機関
• 米国食品医薬品局
• 欧州医薬品庁
• 日本の医薬品医療機器総合機構
• 中国国家薬品監督管理局
• 肝臓薬開発に関する考察

第5章 新たな動向とパイプライン分析

• 新たな動向
• 肝疾患における個別化医療
• 肝移植の進歩
• 再生医療と幹細胞療法
• 肝癌に対する免疫療法
• mRNAによる肝疾患の修復
• パイプライン分析
• 特許分析
• 調査結果

第6章 市場セグメンテーション分析

• セグメンテーションの内訳
• 市場内訳：疾病別
• サマリー
• 肝炎
• 非アルコール性脂肪性肝疾患
• 肝細胞癌
• 自己免疫性肝疾患
• アルコール性肝疾患 (ALD)
• 慢性肝疾患
• その他
• 地理的内訳
• 市場内訳：地域別
• サマリー
• 北米
• 欧州
• アジア太平洋
• 南米
• 中東・アフリカ

第7章 競合情報

• サマリー
• 主要企業ランキング
• 戦略分析
• ベンチャー資金調達と投資

第8章 肝疾患治療産業における持続可能性：ESGの観点

• 概要
• 環境の持続可能性
• 社会的責任
• ガバナンス
• ESGリスク評価
• BCCによる総論

第9章 付録

• 調査手法
• 出典
• 略語
• 企業プロファイル
• ABBVIE INC.
• ASTRAZENECA
• BAYER AG
• BIOTEST AG
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• GILEAD SCIENCES INC.
• GSK PLC.
• INTERCEPT PHARMACEUTICALS INC.
• MADRIGAL PHARMACEUTICALS
• MERCK & CO. INC.
• NOVARTIS AG
• SALIX PHARMACEUTICALS
• SANOFI
• TAKEDA PHARMACEUTICAL CO. LTD.
• 新興スタートアップ企業/市場ディスラプター

List of Tables

• Summary Table : Global Market for Liver Disease Treatments, by Region, Through 2030
• Table 1 : Vaccines for Preventing Hepatitis A and B
• Table 2 : Drugs Used to Treat Autoimmune Liver Diseases
• Table 3 : Porter's Five Forces: Rating Scale
• Table 4 : Estimates of the Burden of Chronic Hepatitis B and C, by WHO Region, 2022
• Table 5 : Possible Side Effects of Liver Treatment Drugs
• Table 6 : FDA Drug Approvals for Liver Treatment, 2022-2024
• Table 7 : EMA Drug Approvals for Liver Treatment, 2024 and 2025
• Table 8 : Drugs Approved by the PMDA for Liver Treatment, 2022-2024
• Table 9 : Pipeline Drugs for Liver Disease Treatment in Phases 3 and 4, 2024
• Table 10 : Granted Patents in Liver Drugs, 2023-2025
• Table 11 : Global Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 12 : Global Market for Treatments for Hepatitis, by Region, Through 2030
• Table 13 : Pipeline Drugs for NAFLD
• Table 14 : Global Market for Treating NAFLD, by Region, Through 2030
• Table 15 : Countries with Highest Incidence of Liver Cancer, 2022
• Table 16 : Global Market for Treating Hepatocellular Carcinoma, by Region, Through 2030
• Table 17 : Global Market for Treating Autoimmune Liver Diseases, by Region, Through 2030
• Table 18 : Global Market for Treating Alcohol-induced Liver Disease, by Region, Through 2030
• Table 19 : Global Market for Treating Chronic Liver Disease, by Region, Through 2030
• Table 20 : Global Market for Treating Other Liver Diseases, by Region, Through 2030
• Table 21 : Global Market for Liver Disease Treatments, by Region, Through 2030
• Table 22 : North American Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 23 : North American Market for Liver Disease Treatments, by Country, Through 2030
• Table 24 : U.S. Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 25 : Canadian Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 26 : Liver Transplants from Donors, Per Center in Mexico, in 2023
• Table 27 : Mexican Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 28 : European Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 29 : European Market for Liver Disease Treatments, by Country, Through 2030
• Table 30 : German Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 31 : Premature Mortality Due to Alcoholic Liver Disease, 2019, 2022, 2023
• Table 32 : U.K. Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 33 : French Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 34 : Spanish Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 35 : Italian Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 36 : Rest of European Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 37 : Asia-Pacific Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 38 : Asia-Pacific Market for Liver Disease Treatments, by Country, Through 2030
• Table 39 : Chinese Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 40 : Japanese Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 41 : Indian Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 42 : Rest of Asia-Pacific Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 43 : South American Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 44 : South American Market for Liver Disease Treatments, by Country, Through 2030
• Table 45 : Brazilian Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 46 : Argentinian Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 47 : Rest of South American Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 48 : MEA Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 49 : MEA Market for Liver Disease Treatments, by Region, Through 2030
• Table 50 : Middle East Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 51 : African Market for Liver Disease Treatments, by Disease Type, Through 2030
• Table 52 : Leading Companies in the Market for Liver Disease Treatments, 2024
• Table 53 : Recent Venture Funding in the Liver Disease Treatment Industry
• Table 54 : ESG Risk Rankings for Pharmaceutical Firms in the Liver Disease Market
• Table 55 : Report Information Sources
• Table 56 : Abbreviations Used in the Report
• Table 57 : AbbVie Inc.: Company Snapshot
• Table 58 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
• Table 59 : AbbVie Inc.: Product Portfolio
• Table 60 : AstraZeneca: Company Snapshot
• Table 61 : AstraZeneca: Financial Performance, FY 2023 and 2024
• Table 62 : AstraZeneca: Product Portfolio
• Table 63 : AstraZeneca: News/Key Developments, 2022 and 2023
• Table 64 : Bayer AG: Company Snapshot
• Table 65 : Bayer AG: Financial Performance, FY 2023 and 2024
• Table 66 : Bayer AG: Product Portfolio
• Table 67 : Bayer AG: News/Key Developments, 2023 and 2024
• Table 68 : Biotest AG: Company Snapshot
• Table 69 : Biotest AG: Financial Performance, FY 2023 and 2024
• Table 70 : Biotest AG: Product Portfolio
• Table 71 : Biotest AG: News/Key Developments, 2023
• Table 72 : Bristol-Myers Squibb Co.: Company Snapshot
• Table 73 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
• Table 74 : Bristol-Myers Squibb Co.: Product Portfolio
• Table 75 : Bristol-Myers Squibb Co.: News/Key Developments, 2025
• Table 76 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 77 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
• Table 78 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 79 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023
• Table 80 : Gilead Sciences Inc.: Company Snapshot
• Table 81 : Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
• Table 82 : Gilead Sciences Inc.: Product Portfolio
• Table 83 : Gilead Sciences Inc.: News/Key Developments, 2024
• Table 84 : GSK plc.: Company Snapshot
• Table 85 : GSK plc.: Financial Performance, FY 2023 and 2024
• Table 86 : GSK plc.: Product Portfolio
• Table 87 : GSK plc.: News/Key Developments, 2024
• Table 88 : Intercept Pharmaceuticals Inc.: Company Snapshot
• Table 89 : Intercept Pharmaceuticals Inc.: Product Portfolio
• Table 90 : Intercept Pharmaceuticals Inc.: News/Key Developments, 2024
• Table 91 : Madrigal Pharmaceuticals: Company Snapshot
• Table 92 : Madrigal Pharmaceuticals: Financial Performance, FY 2023 and 2024
• Table 93 : Madrigal Pharmaceuticals: Product Portfolio
• Table 94 : Madrigal Pharmaceuticals: News/Key Developments, 2024
• Table 95 : Merck & Co. Inc.: Company Snapshot
• Table 96 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
• Table 97 : Merck & Co. Inc.: Product Portfolio
• Table 98 : Merck & Co. Inc.: News/Key Developments, 2024
• Table 99 : Novartis AG: Company Snapshot
• Table 100 : Novartis AG: Financial Performance, FY 2023 and 2024
• Table 101 : Novartis AG: Product Portfolio
• Table 102 : Novartis AG: News/Key Developments, 2022
• Table 103 : Salix Pharmaceuticals: Company Snapshot
• Table 104 : Salix Pharmaceuticals: Product Portfolio
• Table 105 : Salix Pharmaceuticals: News/Key Developments, 2023
• Table 106 : Sanofi: Company Snapshot
• Table 107 : Sanofi: Financial Performance, FY 2023 and 2024
• Table 108 : Sanofi: Product Portfolio
• Table 109 : Sanofi: News/Key Developments, 2024
• Table 110 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
• Table 111 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023
• Table 112 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
• Table 113 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2023 and 2024
• Table 114 : Emerging Startups

List of Figures

• Summary Figure : Shares of Global Market for Liver Disease Treatments, by Region, 2024
• Figure 1 : Porter's Five Forces Analysis
• Figure 2 : Market Dynamics of Liver Disease Treatments
• Figure 3 : Distribution of Death by Liver Diseases in England, by Age Group, 2020
• Figure 4 : Clinical Trial Studies of Liver Treatment Drugs, by Trial Phase, 2024
• Figure 5 : Patent Analysis of Liver Treatment Drugs, 2022-2025
• Figure 6 : Shares of Global Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 7 : Shares of Global Market for Hepatitis Treatments, by Region, 2024
• Figure 8 : Shares of Global Market for Treating NAFLD, by Region, 2024
• Figure 9 : Shares of Global Market for Treating Hepatocellular Carcinoma, by Region, 2024
• Figure 10 : Shares of Global Market for Treating Autoimmune Liver Diseases, by Region, 2024
• Figure 11 : Shares of Global Market for Treating Alcohol-induced Liver Disease, by Region, 2024
• Figure 12 : Shares of Global Market for Treating Chronic Liver Disease, by Region, 2024
• Figure 13 : Shares of Global Market for Treating Other Liver Diseases, by Region, 2024
• Figure 14 : Shares of Global Market for Liver Disease Treatments, by Region, 2024
• Figure 15 : Shares of North American Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 16 : Shares of North American Market for Liver Disease Treatments, by Country, 2024
• Figure 17 : Shares of U.S. Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 18 : Shares of Canadian Market for Liver Diseases Treatments, by Disease Type, 2024
• Figure 19 : Shares of Mexican Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 20 : Shares of European Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 21 : Shares of European Market for Liver Disease Treatments, by Country, 2024
• Figure 22 : Deaths Due to Chronic Liver Disease in Germany, 2011-2021
• Figure 23 : Shares of German Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 24 : Shares of U.K. Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 25 : Shares of French Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 26 : Shares of Spanish Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 27 : Shares of Italian Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 28 : Shares of Rest of European Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 29 : Shares of Asia-Pacific Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 30 : Shares of Asia-Pacific Market for Liver Disease Treatments, by Country, 2024
• Figure 31 : Shares of Chinese Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 32 : Shares of Japanese Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 33 : Shares of Indian Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 34 : Shares of Rest of Asia-Pacific Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 35 : Shares of South American Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 36 : Shares of South American Market for Liver Disease Treatments, by Country, 2023
• Figure 37 : Shares of Brazilian Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 38 : Shares of Argentinian Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 39 : Shares of Rest of South American Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 40 : Shares of MEA Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 41 : Shares of MEA Market for Liver Disease Treatments, by Region, 2024
• Figure 42 : Shares of Middle East Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 43 : Shares of African Market for Liver Disease Treatments, by Disease Type, 2024
• Figure 44 : AbbVie Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 45 : AbbVie Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 46 : AstraZeneca: Revenue Shares, by Business Unit, FY 2024
• Figure 47 : AstraZeneca: Revenue Shares, by Region/Country, FY 2024
• Figure 48 : Bayer AG: Revenue Shares, by Business Unit, FY 2024
• Figure 49 : Bayer AG: Revenue Shares, by Country/Region, FY 2024
• Figure 50 : Biotest AG: Revenue Shares, by Business Unit, FY 2024
• Figure 51 : Biotest AG: Revenue Shares, by Country/Region, FY 2024
• Figure 52 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024
• Figure 53 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024
• Figure 54 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2024
• Figure 55 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2024
• Figure 56 : Gilead Sciences Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 57 : Gilead Sciences Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 58 : GSK plc.: Revenue Shares, by Business Unit, FY 2024
• Figure 59 : GSK plc.: Revenue Shares, by Country/Region, FY 2024
• Figure 60 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 61 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 62 : Novartis AG: Revenue Shares, by Business Unit, FY 2024
• Figure 63 : Novartis AG: Revenue Shares, by Country/Region, FY 2024
• Figure 64 : Sanofi: Revenue Shares, by Business Unit, FY 2024
• Figure 65 : Sanofi: Revenue Shares, by Country/Region, FY 2024
• Figure 66 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, FY 2023
• Figure 67 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Country/Region, FY 2023

The global market for liver disease treatments is estimated to increase from $46.0 billion in 2024 to reach $69.1 billion by 2030, at a compound annual growth rate (CAGR) of 7.1% from 2025 through 2030.

The North American market for liver disease treatments is estimated to increase from $20.8 billion in 2024 to reach $31.6 billion by 2030, at a CAGR of 7.3% from 2025 through 2030.

The Asia-Pacific market for liver disease treatments is estimated to increase from $6.9 billion in 2024 to reach $10.8 billion by 2030, at a CAGR of 7.9% from 2025 through 2030.

Report Scope:

This report on the global market for liver disease treatments provides qualitative and quantitative data on the current market dynamics. It discusses different liver diseases and their treatment modalities.

Analyses of the most frequently used products, clinical trials, new product approvals, and emerging technologies are also included. The demographics of the major regions-North America, Europe, Asia-Pacific, South America, and the Middle East and Africa-as well as their prospects for growth are summarized. The profiles of leading companies in the market and their strategies are also discussed.

The market for liver disease treatments is broken into hepatitis, non-alcoholic fatty liver disease (NAFLD), hepatocellular carcinoma, autoimmune liver diseases, alcohol-induced liver disease (ALD), chronic liver disease, and others. The growth potential and forecast data are discussed for each disease for the aforementioned regions and many countries.

The report includes global revenue in $ millions for the base year of 2024, estimates for 2025, and data for the forecast period of 2026 through 2030.

Report Includes :

• 52 data tables and 63 additional tables
• Analyses of the trends in the global markets for liver disease treatments, with revenue data from 2023, estimates for 2024, forecasts for 2025, and projected CAGRs through 2029
• Estimates of the size and revenue prospects for the global market, along with a market share analysis by product (drug) type, disease type, route of administration, end user, and region
• Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the impacts of macroeconomic variables
• Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
• An assessment of the major drugs that can cause liver disease, the market's current situation and future prospects, clinical trials, new developments, and pipeline products
• An analysis of the key patent grants and recently published patents
• Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
• Analysis of the industry structure, including companies' product offerings, strategic alliances, M&A activity, venture fundings and investment outlook
• Company profiles of major players within the industry, including Gilead Sciences Inc., Bristol Myers Squibb Co., AbbVie Inc., and Merck & Co. Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview
• Classification of Therapies, by Disease and Product
• Hepatitis
• Liver Tumors and Liver Cancer
• Autoimmune Liver Diseases
• Alcohol-induced liver disease
• Chronic Liver Disease
• Non-Alcoholic Fatty Liver Disease
• Analysis of Macroeconomic Factors
• Population Demographics and Aging Population
• Global Economic Growth
• Geopolitical Risks, Trade Wars, and Supply Chain Disruptions
• Public Awareness and Education
• Porter's Five Forces
• Potential for New Entrants (Moderate to Low)
• Bargaining Power of Suppliers (Moderate to High)
• Bargaining Power of Buyers (Moderate to High)
• Threat of Substitute Products or Services (Low to Moderate)
• Industry Competitiveness (High)

Chapter 3 Market Dynamics

• Overview
• Market Drivers
• Increasing Incidence of Liver Diseases
• Consumption of Alcohol and Improper Diet
• Government Initiatives to Provide Vaccines and Grow Awareness
• Market Restraints
• FDA Approvals and Stringent Government Regulations
• Side Effects and Risks Associated with Drugs
• Market Opportunities
• Advances in Treatment Options
• Emerging Markets and Access to Treatment

Chapter 4 Regulatory Landscape

• Global Regulatory Agencies
• U.S. Food and Drug Administration
• European Medicines Agency
• Japan's Pharmaceuticals and Medical Devices Agency
• China's National Medical Products Administration
• Considerations in Liver Drug Development

Chapter 5 Emerging Trends and Pipeline Analysis

• Emerging Trends
• Personalized Medicine in Liver Disease
• Advances in Liver Transplantation
• Regenerative Medicine and Stem Cell Therapy
• Immunotherapy for Liver Cancer
• Repairing Liver Disease with mRNA
• Pipeline Analysis
• Patent Analysis
• Findings

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Market Breakdown, by Disease Type
• Takeaways
• Hepatitis
• Non-Alcoholic Fatty Liver Disease
• Hepatocellular Carcinoma
• Autoimmune Liver Diseases
• Alcohol-induced Liver Disease (ALD)
• Chronic Liver Disease
• Other Liver-Related Diseases
• Geographic Breakdown
• Market Breakdown, by Region
• Takeaways
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa

Chapter 7 Competitive Intelligence

• Takeaways
• Market Ranking of Leading Companies
• Strategic Analysis
• Venture Funding and Investments

Chapter 8 Sustainability in the Liver Disease Treatment Industry: ESG Perspective

• Overview
• Environmental Sustainability
• Social Responsibility (S)
• Governance
• ESG Risk Ratings
• Concluding Remarks from BCC

Chapter 9 Appendix

• Research Methodology
• Sources
• Abbreviations
• Company Profiles
• ABBVIE INC.
• ASTRAZENECA
• BAYER AG
• BIOTEST AG
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• GILEAD SCIENCES INC.
• GSK PLC.
• INTERCEPT PHARMACEUTICALS INC.
• MADRIGAL PHARMACEUTICALS
• MERCK & CO. INC.
• NOVARTIS AG
• SALIX PHARMACEUTICALS
• SANOFI
• TAKEDA PHARMACEUTICAL CO. LTD.
• Emerging Start-ups/Market Disruptors